Adamis Pharmaceuticals Corporation
Index- P/E- EPS (ttm)-0.20 Insider Own0.70% Shs Outstand149.62M Perf Week18.49%
Market Cap79.98M Forward P/E- EPS next Y-0.05 Insider Trans-3.15% Shs Float148.28M Perf Month14.13%
Income-30.90M PEG- EPS next Q-0.03 Inst Own8.70% Short Float4.22% Perf Quarter-6.31%
Sales2.00M P/S39.99 EPS this Y48.10% Inst Trans-8.79% Short Ratio9.16 Perf Half Y-11.87%
Book/sh0.11 P/B4.85 EPS next Y64.30% ROA- Target Price0.42 Perf Year-51.96%
Cash/sh0.12 P/C4.49 EPS next 5Y- ROE- 52W Range0.31 - 1.48 Perf YTD-11.87%
Dividend- P/FCF- EPS past 5Y27.40% ROI-104.50% 52W High-64.31% Beta1.19
Dividend %- Quick Ratio2.00 Sales past 5Y-19.40% Gross Margin- 52W Low69.39% ATR0.05
Employees15 Current Ratio2.00 Sales Q/Q-14.30% Oper. Margin- RSI (14)68.07 Volatility11.09% 9.82%
OptionableYes Debt/Eq0.12 EPS Q/Q36.40% Profit Margin- Rel Volume0.44 Prev Close0.53
ShortableYes LT Debt/Eq0.00 EarningsMay 16 AMC Payout- Avg Volume682.83K Price0.53
Recom3.00 SMA2018.89% SMA5022.31% SMA200-21.15% Volume264,299 Change-0.95%
May-13-20Upgrade Maxim Group Hold → Buy $1.50
Feb-27-20Downgrade Dawson James Buy → Neutral
Nov-26-19Downgrade Raymond James Outperform → Mkt Perform
Jul-16-19Downgrade B. Riley FBR Neutral → Sell $1.90 → $1.10
Nov-12-18Downgrade B. Riley FBR Buy → Neutral $7.50 → $2.50
May-11-18Reiterated Maxim Group Buy $5 → $10
Mar-23-18Reiterated B. Riley FBR, Inc. Buy $6.25 → $7.50
Dec-05-17Reiterated Maxim Group Buy $13 → $14
Oct-04-17Resumed B. Riley & Co. Buy $9.50
Jul-21-16Reiterated Maxim Group Buy $17 → $10
Dec-01-15Initiated Maxim Group Buy $16
May-29-15Initiated Mizuho Buy $10
Jan-28-14Initiated CRT Capital Buy $15
Jun-01-22 08:00AM  
May-31-22 12:00PM  
May-26-22 04:05PM  
May-18-22 05:00PM  
May-16-22 04:35PM  
May-09-22 05:56PM  
Mar-31-22 04:49PM  
Mar-30-22 05:15PM  
Mar-29-22 08:15PM  
Mar-28-22 05:25PM  
Mar-24-22 07:30AM  
Mar-22-22 07:30AM  
Mar-21-22 04:05PM  
Mar-14-22 08:17AM  
Mar-04-22 07:30AM  
Feb-28-22 07:30AM  
Feb-18-22 04:05PM  
Feb-07-22 09:17AM  
Jan-10-22 07:30AM  
Dec-20-21 10:00AM  
Dec-01-21 07:30AM  
Nov-23-21 02:39PM  
Nov-22-21 04:47PM  
Nov-19-21 03:34PM  
Oct-18-21 08:55AM  
Oct-11-21 05:44PM  
Oct-04-21 07:30AM  
Sep-03-21 12:12PM  
Sep-02-21 10:56AM  
Aug-24-21 04:05PM  
Aug-19-21 07:30AM  
Aug-04-21 04:05PM  
Jul-19-21 04:05PM  
Jul-13-21 08:00AM  
Jul-01-21 08:00AM  
Jun-28-21 07:00AM  
Jun-18-21 08:32AM  
Jun-14-21 09:00AM  
Jun-13-21 02:11PM  
Jun-11-21 07:30AM  
Jun-09-21 07:30AM  
Jun-07-21 09:51AM  
Jun-01-21 07:30AM  
May-28-21 04:04PM  
May-26-21 03:00PM  
May-25-21 07:42PM  
May-17-21 04:05PM  
May-12-21 07:30AM  
Apr-15-21 04:39PM  
Apr-13-21 04:03PM  
Apr-12-21 10:28AM  
Mar-22-21 12:30PM  
Mar-15-21 09:00AM  
Feb-22-21 09:00AM  
Feb-17-21 12:00PM  
Feb-02-21 04:05PM  
Jan-29-21 09:00AM  
Jan-28-21 04:01PM  
Jan-26-21 09:00AM  
Jan-22-21 10:47AM  
Jan-21-21 06:39PM  
Jan-20-21 01:06PM  
Jan-08-21 08:30AM  
Dec-01-20 09:00AM  
Nov-18-20 12:24PM  
Nov-16-20 11:55AM  
Nov-09-20 06:35PM  
Nov-05-20 09:00AM  
Nov-03-20 12:30PM  
Oct-12-20 10:24AM  
Sep-18-20 09:00AM  
Sep-17-20 04:05PM  
Sep-16-20 09:23AM  
Sep-03-20 04:05PM  
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, and injectables; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Moss Ronald B.Chief Medical OfficerMar 18Sale0.608,1994,949201,911Mar 22 06:39 PM
Marguglio David J.SVP and Chief Business OfficerMar 18Sale0.6011,8597,117233,906Mar 22 06:39 PM
CARLO DENNIS J PHDPresident & CEOMar 18Sale0.6010,4906,287285,867Mar 22 06:37 PM
Benedicto David C.Chief Financial OfficerMar 18Sale0.613,6032,20839,875Mar 22 06:35 PM
Benedicto David C.Chief Financial OfficerDec 01Sale0.7913,55410,64043,478Dec 03 05:10 PM
Marguglio David J.SVP and Chief Business OfficerDec 01Sale0.7950,75739,844258,765Dec 03 05:09 PM
Moss Ronald B.Chief Medical OfficerDec 01Sale0.7935,55327,909210,110Dec 03 05:10 PM
CARLO DENNIS J PHDPresident & CEODec 01Sale0.7947,87037,578296,357Dec 03 05:08 PM